Cleve Clin J Med 2017 Dec;84(12 Suppl 3):12-26
Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, USA.
|PDF Download - Full Text Link
( Please be advised that this article is hosted on an external website not affiliated with PubFacts.com)
Amyloid 2017 Dec 14;24(4):226-230. Epub 2017 Sep 14.
a Clinical Cardiovascular Research Laboratory for the Elderly , Columbia University Medical Center, Allen Hospital of New York-Presbyterian Hospital , New York , NY , USA.
Transthyretin cardiac amyloidosis (ATTR-CA) causes a restrictive cardiomyopathy in older adults, often diagnosed at advanced stages when emerging therapies in late phase clinical trials may not have clinical benefit. This investigation aimed to detect clinical entities that may provide more advanced warning of ATTR-CA. Since ATTR preferentially deposits in ligaments, tendons, and articular cartilage, we hypothesized that ATTR-CA patients have a greater prevalence of total hip (THA) and knee (TKA) arthroplasties compared with the general population, and that arthroplasty occurs significantly before ATTR-CA diagnosis. Read More
Curr Treat Options Cardiovasc Med 2018 Apr 7;20(5):37. Epub 2018 Apr 7.
Cardiovascular Division, Cardio-Oncology Center of Excellence, Washington University in St Louis, 660 South Euclid Avenue, Campus Box 8086, St Louis, MO, 63110, USA.
Systemic amyloidosis represents a complex group of diseases with a common feature characterized by misfolded autologous proteins depositing into tissues or organs throughout the body. Light chain amyloidosis (AL) and transthyretin (TTR) amyloid are the two most prevalent forms of this disease that commonly results in cardiac amyloidosis. In both of these conditions, the myocardium is a frequent site of infiltration and end-organ involvement often with devastating consequences. Read More
JACC Cardiovasc Imaging 2014 Feb 8;7(2):133-42. Epub 2014 Jan 8.
Cardiovascular Sciences, St. George's University of London, London, United Kingdom.
Objectives: This study was devised to describe the different cardiac magnetic resonance (CMR) appearances in light chain amyloid (AL) and transthyretin-related amyloidosis (ATTR).
Background: CMR is increasingly used to investigate patients with suspected amyloidosis. Global subendocardial late gadolinium enhancement (LGE) has been reported as typical of AL amyloidosis, whereas different patterns have been noted in ATTR amyloidosis. Read More
JACC Cardiovasc Imaging 2014 Feb 8;7(2):157-65. Epub 2014 Jan 8.
The Heart Hospital, London, United Kingdom; Institute of Cardiovascular Science, University College London, London, United Kingdom. Electronic address:
Objectives: The aims of the study were to explore the ability of native myocardial T1 mapping by cardiac magnetic resonance to: 1) detect cardiac involvement in patients with transthyretin amyloidosis (ATTR amyloidosis); 2) track the cardiac amyloid burden; and 3) detect early disease.
Background: ATTR amyloidosis is an underdiagnosed cause of heart failure, with no truly quantitative test. In cardiac immunoglobulin light-chain amyloidosis (AL amyloidosis), T1 has high diagnostic accuracy and tracks disease. Read More